Study of antiviral activity of a new plant origin preparation neoflazidum on a model of the hepatitis c virus
This paper presents some results concerning investigation of antiviral activity of a new plant origin preparation - neoflazidum, a form of proteflazidum - using a model of hepatitis C virus-producing Jurkat cell culture (Jurkat HCV ) which has been previously transfected with complementary DNA preparations isolated from different types of hepatitis C virus (HCV). To obtain these preparations, HCV RNA preparations were isolated from viral material of HCV-diseased patients, the transfecting agent Turbofect being used. The cytotoxic dose (CD50) was shown to be 37.2 μg/ml, the effective dose (ED50) being 0.46 μg/ml for the HCV type 3a; this dose, however, was as high as 3.7 μg/ml when neoflazidum had been tested for HCV type 1b. Therefore, the selectivity index for the HCV type 3a reached 80.8 in the Jurkat HCV-3a cell system, being as low as 10.0 for the HCV type 1b. Using a model system RNAP T7, the antiviral neoflazidum activity was demonstrated to be realized due to interferons α- and γ-induction and RNA synthesis inhibition.